Generic placeholder image

Coronaviruses

Editor-in-Chief

ISSN (Print): 2666-7967
ISSN (Online): 2666-7975

Research Article

COVID-19 Epigenetics and Implications for Public Health

Author(s): Verda Tunaligil, Gülsen Meral, Ahmet Kati*, Dhrubajyoti Chattopadhyay and Amit Kumar Mandal*

Volume 2, Issue 2, 2021

Published on: 05 October, 2020

Page: [235 - 240] Pages: 6

DOI: 10.2174/2666796701999201005212515

Abstract

Background: COVID-19 debilitated communities globally in varying complexities and capacities in recent months.

Objective: The epigenetic changes in the COVID-19 patients were discussed in this article to explore various processes contributing to disease severity and elevation of risk due to infection.

Methods: Percentages of hospitalization, with and without intensive care, in the presence of diseases with increased ACE2 expression, were compared, based on the best available data. Further analysis compared two different age groups, 19-64 and ≥65 years of age.

Result & Conclusion: The COVID-19 disease is observed to be the most severe in the 65 and-higher-age group with pre-existing chronic conditions. This observational study is a nonexperimental empirical investigation of the outcomes of COVID-19 in different patient groups. Results are promising for conducting clinical trials with intervention groups. To ultimately succeed in disease prevention, researchers and clinicians must integrate epigenetic mechanisms to generate valid prescriptions for global well-being.

Keywords: COVID-19, epigenetic, communicable and non-communicable disease, chronic illness, public health, SARS-CoV-2.

[1]
Gwinn M, MacCannell DR, Khabbaz RF. Integrating advanced molecular technologies into public health. J Clin Microbiol 2017; 55(3): 703-14.
[http://dx.doi.org/10.1128/JCM.01967-16] [PMID: 28031438]
[2]
Evans JP, Powell BC, Berg JS. Finding the rare pathogenic variants in a human genome. JAMA 2017; 317(18): 1904-5.
[http://dx.doi.org/10.1001/jama.2017.0432] [PMID: 28492888]
[3]
Gwinn M, MacCannell D, Armstrong GL. Next-generation sequencing of infectious pathogens. JAMA 2019; 321(9): 893-4.
[http://dx.doi.org/10.1001/jama.2018.21669] [PMID: 30763433]
[4]
Hu Y, Sun J, Dai Z, et al. Prevalence and severity of corona virus disease 2019 (COVID-19): a systematic review and meta-analysis. J Clin Virol 2020; 127104371
[http://dx.doi.org/10.1016/j.jcv.2020.104371] [PMID: 32315817]
[5]
Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents 2020; 55(3)105924
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105924] [PMID: 32081636]
[6]
Centers for Disease Control and Prevention, . Assessing risk Factors for severe COVID-19 illnessAvailable from: https://www.cdc.gov/coronavirus/2019-ncov/COVID-data/investigations-discovery/assessing-risk-factors.html
[7]
Centers for Disease Control and Prevention, People who are at higher risk for severe illness Available from: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-higher-risk.html
[8]
Ahmed T, Noman M, Almatroudi A, et al. Coronavirus disease 2019 assosiated pneumonia in China: current status and future prospects. Preprints 2020; 2020: 1.
[http://dx.doi.org/10.20944/preprints202002.0358.v3]
[9]
Ji W, Wang W, Zhao X, Zai J, Li X. Cross-species transmission of the newly identified coronavirus 2019-nCoV. J Med Virol 2020; 92(4): 433-40.
[http://dx.doi.org/10.1002/jmv.25682] [PMID: 31967321]
[10]
Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. Lancet 2020; 395(10229): 1014-5.
[http://dx.doi.org/10.1016/S0140-6736(20)30633-4] [PMID: 32197108]
[11]
Chow N, Fleming-Dutra K, Gierke R, et al. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 — United States, February 12–March 28, 2020. Morb Mortal Week Rep 2020; 69(13): 382-6..
[12]
Gal-Oz ST, Maier B, Yoshida H, et al. ImmGen report: sexual dimorphism in the immune system transcriptome. Nat Commun 2019; 10(1): 4295.
[http://dx.doi.org/10.1038/s41467-019-12348-6] [PMID: 31541153]
[13]
Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect 2020; 81(2): e16-25.
[http://dx.doi.org/10.1016/j.jinf.2020.04.021] [PMID: 32335169]
[14]
Corley MJ, Ndhlovu LC. DNA methylation analysis of the COVID-19 host cell receptor, Angiotensin I converting enzyme 2 gene (ACE2) in the respiratory system reveal age and gender differences. Preprints 2020; 2020: 1.
[http://dx.doi.org/10.20944/preprints202003.0295.v1]
[15]
Pinto BGG, Oliveira AER, Singh Y, et al. ACE2 expression is increased in the lungs of patients with comorbidities associated with severe COVID-19. J Infect Dis 2020; 222(4): 556-63.
[http://dx.doi.org/10.1093/infdis/jiaa332]
[16]
Matthay MA, Zemans RL. The acute respiratory distress syndrome: pathogenesis and treatment. Annu Rev Pathol 2011; 6: 147-63.
[http://dx.doi.org/10.1146/annurev-pathol-011110-130158] [PMID: 20936936]
[17]
Zhang G, Hu C, Luo L, et al. Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China. J Clin Virol 2020; 127104364
[http://dx.doi.org/10.1016/j.jcv.2020.104364] [PMID: 32311650]
[18]
Chen C-M, Lu H-C, Tung Y-T, Chen W. Antiplatelet therapy for acute respiratory distress syndrome. Biomedicines 2020; 8(7): 230.
[http://dx.doi.org/10.3390/biomedicines8070230] [PMID: 32708068]
[19]
Jirtle RL, Skinner MK. Environmental epigenomics and disease susceptibility. Nat Rev Genet 2007; 8(4): 253-62.
[http://dx.doi.org/10.1038/nrg2045] [PMID: 17363974]
[20]
Sarigöl Z, Bucurgat U. Epigenetik Değişiklikler ve Beslenme İlişkisi. J Lit Pharm Sci 2014; 3: 74-80.
[http://dx.doi.org/10.5336/pharmsci.2015-44039]
[21]
Zill P, Baghai TC, Schüle C, et al. DNA methylation analysis of the angiotensin converting enzyme (ACE) gene in major depression. PLoS One 2012; 7(7)e40479https://doi.org/https://dx.doi.org/10.1371%2Fjournal.pone.0040479
[http://dx.doi.org/10.1371/journal.pone.0040479] [PMID: 22808171]
[22]
Boulias K, Lieberman J, Greer EL. An epigenetic clock measures accelerated aging in treated HIV infection. Mol Cell 2016; 62(2): 153-5.
[http://dx.doi.org/10.1016/j.molcel.2016.04.008] [PMID: 27105110]
[23]
Salimi S, Hamlyn JM. COVID-19 and crosstalk between the hallmarks of aging. Preprints 2020; 2020: 1.
[http://dx.doi.org/10.20944/preprints202004.0182.v2]
[24]
Komatsu T, Suzuki Y, Imai J, et al. Molecular cloning, mRNA expression and chromosomal localization of mouse angiotensin-converting enzyme-related carboxypeptidase (mACE2). DNA Seq 2002; 13(4): 217-20.
[http://dx.doi.org/10.1080/1042517021000021608] [PMID: 12487024]
[25]
Sawalha AH, Zhao M, Coit P, Lu Q. Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients. Clin Immunol 2020; 215108410https://doi.org/https://doi.org/10.1016/j.clim.2020.108410
[http://dx.doi.org/10.1016/j.clim.2020.108410] [PMID: 32276140]
[26]
Rao S, Lau A, So H-C. Exploring diseases/traits and blood proteins causally related to expression of ACE2, the putative receptor of SARS-CoV-2: a mendelian randomization analysis highlights tentative relevance of diabetes-related traits. Medrxiv 2020; 2020: 1.. https://doi.org/https://doi.org/10.1101/2020.03.04.20031237
[27]
Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am J Physiol Endocrinol Metab 2020; 318(5): E736-41.
[http://dx.doi.org/10.1152/ajpendo.00124.2020] [PMID: 32228322]
[28]
Kaparianos A, Argyropoulou E. Local renin-angiotensin II systems, angiotensin-converting enzyme and its homologue ACE2: their potential role in the pathogenesis of chronic obstructive pulmonary diseases, pulmonary hypertension and acute respiratory distress syndrome. Curr Med Chem 2011; 18(23): 3506-15.
[http://dx.doi.org/10.2174/092986711796642562] [PMID: 21756232]
[29]
Zhifeng J, Feng A, Li T. Consistency analysis of COVID-19 nucleic acid tests and the changes of lung CT. J Clin Virol 2020; 127104359
[http://dx.doi.org/10.1016/j.jcv.2020.104359] [PMID: 32302956]
[30]
Patel AB, Verma A. COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence? JAMA 2020; 323(18): 1769-70.
[http://dx.doi.org/10.1001/jama.2020.4812] [PMID: 32208485]
[31]
Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020; 8(4): 420-2.
[http://dx.doi.org/10.1016/S2213-2600(20)30076-X] [PMID: 32085846]
[32]
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]
[33]
Fabre A, Morand A, Urbina D. COVID-19 and Kawasaki like disease: the known-known, the unknown-known and the unknown-unknown. Preprints 2020; 2020: 1.
[http://dx.doi.org/10.20944/preprints202005.0160.v1]
[34]
Coit P, Direskeneli H, Sawalha AH. An update on the role of epigenetics in systemic vasculitis. Curr Opin Rheumatol 2018; 30(1): 4-15.
[http://dx.doi.org/10.1097/BOR.0000000000000451] [PMID: 28957963]
[35]
Jones VG, Mills M, Suarez D, et al. COVID-19 and Kawasaki disease: novel virus and novel case. Hosp Pediatr 2020; 10(6): 537-40.
[http://dx.doi.org/10.1542/hpeds.2020-0123] [PMID: 32265235]
[36]
Schäfer A, Baric RS. Epigenetic landscape during coronavirus infection. Pathogens 2017; 6(1): E8
[http://dx.doi.org/10.3390/pathogens6010008] [PMID: 28212305]
[37]
Centers for Disease Control and Prevention, Epigenetics and public health: why we should pay attentionAvailable from: https://blogs.cdc.gov/genomics/2014/10/09/epigenetics/n.d
[38]
Rozek LS, Dolinoy DC, Sartor MA, Omenn GS. Epigenetics: relevance and implications for public health. Annu Rev Public Health 2014; 35: 105-22.
[http://dx.doi.org/10.1146/annurev-publhealth-032013-182513] [PMID: 24641556]

© 2022 Bentham Science Publishers | Privacy Policy